Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Results of Reevaluation Now Distributed in 4 Ways
December 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 20, 2004
- BUSINESS NEWS IN BRIEF -1-
December 20, 2004
- BULLETIN
December 20, 2004
- Very Few Clinical Papers in Japan Suitable as Evidence: Expert
December 13, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 13, 2004
- Dainippon Stresses Need for "Critical Mass" via Merger
December 13, 2004
- Press Seminar
December 13, 2004
- BULLETIN
December 13, 2004
- OTC NEWS IN BRIEF
December 13, 2004
- Schering-Plough Expanding MR Force for New Product Launches: Mr Torii
December 13, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 13, 2004
- JPMA to Amend Charter for Good Corporate Conduct
December 13, 2004
- 3 Qtrs Business Results
December 13, 2004
- BUSINESS NEWS IN BRIEF
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 13, 2004
- 8 Drugs Including PegIntron to Be Added to NHI List
December 13, 2004
- Astellas "1st Step Toward Becoming a Global Mega-pharma": Dr Aoki
December 13, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…